Fenna Phibbs is a Neurology physician. OpenAlex indexes 86 publications with 1,660 citations (h-index 23); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 The Vanderbilt Clinic
Nashville, TN 372322551
Telephone
615-322-3000Provider last certified this registry record 30 Mar 2022.
Clinical trials
- Hub and Spoke, Comparative Outcomes for Parkinson's Disease Treated With Deep Brain Stimulation
Sponsor: Vanderbilt University
- Deep Brain Stimulation (DBS) Frequency Effects on Gait in Parkinson's Disease(PD)
Sponsor: Vanderbilt University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year20241 payment
- Boston Scientific CorporationProgram year20241 payment
- Boston Scientific CorporationProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
91.9%Aromatic Amino Acid Decarboxylation Inhibitor36.1%Carbidopa-Levodopa63%Carbidopa-Levodopa Er28%Carbidopa-Levodopa-Entacapone5%Rytary4%Part D<11 patientsAtypical Antipsychotic9.7%Clozapine59%Quetiapine Fumarate32%Quetiapine Fumarate Er5%Nuplazid5%Part D<11 patients+ 16 more classes in this area
Cardiovascular
3.7%alpha-Adrenergic Agonist2%Midodrine Hcl100%Part D≥14 patientsBeta blocker1.2%Propranolol Hcl100%Part D<11 patients+ 1 more class in this area
Musculoskeletal
1.7%gamma-Aminobutyric Acid-ergic Agonist1.7%Baclofen100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”